Genomic Profiling

genomic testing laboratory technician

A genomic profile is more than just a test. Our assays provide biomarker information with the hope of matching patients to approved targeted therapies, immunotherapies, and clinical trials — giving doctors and patients potentially powerful actionable insights for navigating cancer care.

QUICK GUIDE TOOL

Review our Interactive Quick Guide to learn more about Genomic Profiling.

Launch The Quick Guide
x

EVERY CANCER IS UNIQUE

Cancer occurs when the DNA in a human cell becomes damaged or mutates in such a way that the body is unable to identify the problem or repair it. These abnormal cells can grow out of control and form tumours or masses that invade healthy tissue and organs.

Traditionally, cancer has been categorized according to its location in the body, such as lung cancer, breast cancer, etc., and most patients with a particular tumour type are treated based on its categorization by location in the body.

Cancer researchers have identified specific genes that are related to cancer growth. As a result, cancer can now also be categorized by the underlying changes in DNA, or genomic alterations that drive the tumour’s growth.1

A patient

Targeted therapy is a type of cancer treatment designed to be specific to tumours that harbour the appropriate genomic alteration. Targeted therapy is a growing part of many cancer treatment regimens.2

Genomic testing or profiling identifies the underlying DNA alterations that may be driving the tumour’s growth.3 This information may help physicians understand which potential next steps are available for a patient based on their tumour’s unique genomic profile.

Comprehensive genomic profiling with FMI also looks at complex genomic signatures that most standard tests can't assess. The latest science indicates that these new kinds of biomarkers can help a physician better understand the potential role immunotherapies may play for any given patient's disease.

FIND OUT HOW GENOMIC PROFILING A TUMOUR CAN HELP YOU

COMPREHENSIVE† GENOMIC PROFILING CAN HELP TAILOR YOUR NEXT STEP

Even when two people have tumours in the same part of their body, their tumours are most likely different at a basic, molecular level – that is, there may be different genomic alterations causing each person’s cancer to grow.1

Comprehensive† Genomic Profiling cancer tests such as FoundationOne®CDx, FoundationOne®Heme and FoundationOne®Liquid CDx may provide the information your physician needs in one single test to help guide or tailor your next step. You and your doctor can potentially use the results from FoundationOne®CDx, FoundationOne®Heme and FoundationOne®Liquid CDx to better understand your disease and may be able to identify approved targeted therapies, immunotherapies or therapies under development in clinical trials.

Talk to your doctor about Comprehensive† Genomic Profiling and learn how you may benefit from creating a tailored plan.

FOUNDATION TESTS AVAILABLE IN CANADA

Our Diagnostic Portfolio

  • Foundation Medicine Symbol
  • CONDITION
  • SAMPLE TYPE
  • GENOMIC SIGNATURES
  • FoundationOne®CDx
  • NSCLC, CRC, Melanoma, and other solid tumours
  • FFPE tissue
  • MSI, TMB
  • Details →
  • FoundationOne®Heme
  • Haematologic malignancies and sarcomas
  • FFPE tissue, Peripheral Whole Blood, Bone Marrow Aspirate
  • MSI, TMB
  • Details →
  • FoundationOne®Liquid CDx
  • Solid tumour
  • Peripheral Whole Blood
  • MSI, bTMB
  • Details →

NSCLC - Non-Small Cell Lung Cancer; CRC - Colorectal Cancer; FFPE - Formalin‑fixed, Paraffin‑embedded; MSI - Microsatellite Instability; TMB - Tumour Mutational Burden; bTMB - blood Tumour Mutational Burden;

Overview

HOW DOES IT WORK?

  • Step 1

    clipboard with test order icon

    Physician orders the test from Foundation Medicine through FoundationNavigate

  • Step 2

    microscope icone

    Pathologist prepares tumour sample and ships to Foundation Medicine

    OR

    blood drop icon

    Blood sample is collected and shipped to Foundation Medicine

  • Step 3

    sample slides icon

    Foundation Medicine receives the sample

  • Step 4

    book icon

    DNA is extracted from the sample

  • Step 5

    computer icon

    Foundation Medicine determines the unique genomic code of the tumour

  • Step 6

    idea - lightbulb icon

    A team of genomic experts analyze the data and determine potential next steps for each patient based on the genomic alterations identified

  • Step 7

    paperreport icon

    Report generated and sent to your physician

Results & Reporting

Test results are provided directly to physicians in a report that highlights the genomic alterations in a patient’s cancer and includes information to help inform next steps. Everything in the report is supported by up-to-date clinical findings and scientific research.

paperreport icon
See a Sample Report

Are you a person living with cancer ready to talk to your doctor about genomic profiling?

Foundation Medicine Tests are ordered by your healthcare provider. Our Ask Your Doctor pamphlet has all the information you and your doctor need to discuss Foundation Medicine testing.
Download Patient Brochure

FoundationOne CDx

† Comprehensive Genomic Profiling with FoundationOne CDx involves:

  • Next generation sequencing of the 324 cancer-related genes known to be clinically relevant to solid tumours
  • Uniform coverage across the entire coding sequence of each gene plus select introns from 36 genes frequently rearranged in cancer
  • Use of hybrid-capture technology to identify base substitutions, insertions/deletions, copy number alterations and rearrangements

FoundationOne Heme

† Comprehensive Genomic Profiling with FoundationOne Heme involves:

  • Next generation sequencing of the 405 cancer-related genes known to be clinically relevant to hematologic malignancies
  • RNA sequencing of 265 genes to capture a broad range of gene fusions that are known to occur in human hematologic malignancies
  • Uniform coverage across the entire coding sequence of each gene plus select introns from 31 genes frequently rearranged in cancer
  • Use of hybrid-capture technology to identify base substitutions, insertions/deletions, copy number alterations and rearrangements

FoundationOne Liquid CDx

† Comprehensive Genomic Profiling with FoundationOne Liquid CDx involves:

  • Next generation sequencing of 324 cancer-related genes
  • Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes
  • Use of hybrid-capture technology to identify base substitutions, insertions/deletions, copy number alterations and rearrangements
  • Detects tumour fraction, microsatellite instability high (MSI-H) status and blood tumour mutational burden (bTMB)
  1. Canadian Cancer Society website at Cancer.ca. Available at: http://www.cancer.ca/en/cancer-information/cancer-101/what-is-cancer/ Accessed on: May 18, 2018.
  2. Canadian Cancer Society website at Cancer.ca. Available at: http://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/chemotherapy-and-other-drug-therapies/targeted-therapy/ Accessed on May 18, 2018.
  3. The Cancer Genome Atlas at cancergenome.nih.gov. Available at: https://cancergenome.nih.gov/cancergenomics/whatisgenomics/whatis. Accessed on May 18, 2018.

FoundationOne®CDx, FoundationOne®Heme and FoundationOne®Liquid CDx are next-generation sequencing services performed by Foundation Medicine, Inc. at laboratories located in Cambridge, Massachusetts, USA. Hoffmann-La Roche Limited markets these services in Canada under an exclusive license from Foundation Medicine, Inc. The FoundationOne®CDx, FoundationOne®Heme and FoundationOne®Liquid CDx reports are prepared exclusively by Foundation Medicine, Inc., without Hoffmann-La Roche Limited’s involvement. The reports may include scientific information about experimental medicinal product(s) or uses that are not approved and/or available in Canada. Hoffmann-La Roche Limited does not endorse or recommend the unapproved use of any medicinal product. FoundationOne® and FoundationOne®CDx are registered trade-marks of Foundation Medicine, Inc., used under license.

Privacy Policy | Terms of Use | Cookie Preferences
© 2024 Hoffmann-La Roche Limited

This website contains information intended for a Canadian audience only, and may contain information or treatment options that are not valid or accessible in other countries. We are not responsible for the access or use outside of Canada of any information on this website which may not comply with laws and regulations applicable outside of Canada.

This website is neither intended nor designed to record or report adverse event information. If you have a suspected side effect or problem to report regarding a Roche product, please email [email protected] or call 1-888-762-4388. You can also report adverse events relating to any product to Health Canada directly by going to the Canada Vigilance Program website at https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html.